PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
94.81%
Net income growth above 1.5x AGEN's 24.62%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-170.14%
Both reduce yoy usage, with AGEN at -122.81%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy AP while AGEN is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-452.30%
Negative yoy usage while AGEN is 56847.04%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
No Data
No Data available this quarter, please select a different quarter.
12.59%
Some CFO growth while AGEN is negative at -1.16%. John Neff would note a short-term liquidity lead over the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Stock issuance far above AGEN's 106.47%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.